Skip to content

Comparing different ways to help people stop using smokeless tobacco products in India, Pakistan and Bangladesh

Addressing Smokeless Tobacco Research and capacity building in South Asia (ASTRA): A randomised, controlled, feasibility trial for smokeless tobacco cessation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN65109397
Enrollment
264
Registered
2019-09-17
Start date
2019-10-01
Completion date
Unknown
Last updated
2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smokeless tobacco use Mental and Behavioural Disorders

Interventions

This is a multi-country, factorial design, feasibility trial of nicotine replacement and behavioral support. Once they have agreed to participate, participants will be asked to provide information abo
those who do not receive an active intervention (arm 1) will receive very brief advice (VBA) along with a self-help leaflet for stopping smokeless tobacco use. The trial will be unblinded, and assignm

Sponsors

University of York
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Self-reported daily user of ST products at least for the last 6 months or ST use on >25 days in the past month 2. Aged >18 years at the time of recruitment 3. Able to provide informed consent 4. Motivated and willing to quit ST use within the next 30 days.

Exclusion criteria

Exclusion criteria: 1. Self-reported users of any combustible tobacco product (cigarettes, bidis, hookah) or e-cigarettes in the past 30 days or those having carbon monoxide (CO) levels >10 ppm, identified by breath test 2. Pregnant or breastfeeding women 3. Individuals with health conditions that warrant caution in using NRT and have previously been excluded in trials of nicotine replacement in smoking. These will be assessed by participant self-report at the pre-trial screening by asking participants whether they have suffered angina pectoris, myocardial infarction or stroke in the past 3 weeks. 4. Individuals who are already on an existing treatment, either pharmacological or behavioral, for tobacco cessation 5. ST-using individuals with diagnosis of oral cancer. Due to the nature of care required, any such individuals identified during the recruitment process will receive a direct referral to specialist care for treatment.

Design outcomes

Primary

MeasureTime frame
1. Self-reported continuous abstinence to all forms of tobacco (smoked and smokeless) at 26 weeks after the quit date, verified by carbon monoxide breath test and salivary cotinine assessment. Participants will be asked a set of questions (one for each type of tobacco product) asking: "have you used this product at all since your quit date?" The possible responses are: no, not even once; yes, 1- 5 times; yes, >5 times. Participants who report consuming tobacco <5 times since quit date, as well as having CO levels that are consistent with abstinence, will be considered as abstinent. 2. Feasibility of conducting a full trial on smokeless tobacco cessation, particularly the feasibility of delivering the intervention, recruitment, randomisation and retention, as well as measures for data collection in a full trial, will be demonstrated through analysis of trial data, as well as preliminary process evaluation and economic assessments

Secondary

MeasureTime frame
Point abstinence to all forms of tobacco (smoked and smokeless) at 6 and 12 weeks following quit date. Participants will be asked about the their tobacco use (all forms) in the past 7 days. Those who report not to have used any tobacco product in the past 7 days will be labelled as abstinent, while those who have used any tobacco product >5 times will be labelled as non-abstinent.

Countries

Bangladesh, India, Pakistan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026